Congratulations to our client Cour Pharmaceuticals Development Co., Inc. on their appointment of Paul Peloso as Chief Medical Officer.
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles aims to treat the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.
C1 Team: Christos Richards and James Reynolds